Protalix BioTherapeutics (PLX) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $1.23 +4.24%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
SFST, VLTO, CLIR, More
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.75 million versus the consensus estimate of $15.1 million.
Cash, cash equivalents and short-term bank deposits were approximately $28.6 million at June 30, 2022.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Preferred Bank (PFBC) Tops Q1 EPS by 6c
- Popular (BPOP) Misses Q1 EPS by 45c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
